Passa al contenuto
Merck
Tutte le immagini(3)

Key Documents

View All Documentation

17850

Sigma-Aldrich

Ciprofloxacin

≥98% (HPLC)

Sinonimo/i:

1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid, Ciprobay

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Formula empirica (notazione di Hill):
C17H18FN3O3
Numero CAS:
85721-33-1
Peso molecolare:
331.34
Beilstein:
3568352
Numero MDL:
MFCD00185755
Codice UNSPSC:
41116105
ID PubChem:
329751572
NACRES:
NA.21

agenzia

EPA 1694

Livello qualitativo

200

Saggio

≥98% (HPLC)

Forma fisica

powder or crystals

Spettro attività antibiotica

Gram-negative bacteria
Gram-positive bacteria

applicazioni

environmental

Modalità d’azione

DNA synthesis | interferes
enzyme | inhibits

Stringa SMILE

OC(=O)C1=CN(C2CC2)c3cc(N4CCNCC4)c(F)cc3C1=O

InChI

1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
MYSWGUAQZAJSOK-UHFFFAOYSA-N

Informazioni sul gene

human ... CYP1A2(1544) , KCNH1(3756)
rat ... Gabra1(29705)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

Ciprofloxacin is a second-generation broad-spectrum fluoroquinolone antibiotic with extensive antimicrobial and pharmacokinetic properties that is widely used to combat bacterial infections. Its chemical name is 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid.

Chemical structure: fluoroquinolone

Applicazioni

Ciprofloxacin is widely used in clinical practices against Gram-positive and Gram-negative bacteria and the treatment of a broad range of infections, including those of the skin, eyes, urinary tract, lower respiratory tract, gastrointestinal tract, et cetera. It can also be combined with various antimicrobial agents to combat bacterial biofilms as well as multidrug-resistant microorganisms. Its derivatives have been developed to synthesize novel antibacterials with enhanced potency and diverse antimicrobial effects including antibacterial, antifungal, anti-HIV, anti-tumor, and anti-TB properties.

Azioni biochim/fisiol

The mechanism of action of Ciprofloxacin is the inhibition of bacterial DNA synthesis by blocking the subunit A of DNA gyrase enzyme as well as by affecting the bacterial cell wall.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
WXBD1572V
049M4087V
049M4087V
047M4024V
WXBC8729V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Ciprofloxacin hydrochloride for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000199

Ciprofloxacin hydrochloride for peak identification

Levofloxacin 98.0-102.0% anhydrous basis (HPLC)

Sigma-Aldrich

28266

Levofloxacin

Piperacillina penicillin analog

Sigma-Aldrich

P8396

Piperacillina

Ciprofloxacin-d8 VETRANAL®, analytical standard

Supelco

32982

Ciprofloxacin-d8

Ciprofloxacin impurity standard British Pharmacopoeia (BP) Reference Standard

BP930

Ciprofloxacin impurity standard

Ofloxacin fluoroquinolone antibiotic

Sigma-Aldrich

O8757

Ofloxacin

Athina Andrea et al.
Microorganisms, 7(3) (2019-03-22)
Among non-mammalian infection model organisms, the larvae of the greater wax moth Galleria mellonella have seen increasing popularity in recent years. Unlike other invertebrate models, these larvae can be incubated at 37 °C and can be dosed relatively precisely. Despite
Elena B M Breidenstein et al.
Antimicrobial agents and chemotherapy, 52(12), 4486-4491 (2008-10-01)
Pseudomonas aeruginosa offers substantial therapeutic challenges due to its high intrinsic resistance to many antibiotics and its propensity to develop mutational and/or adaptive resistance. The PA14 comprehensive mutant library was screened for mutants exhibiting either two- to eightfold increased susceptibilities
Orjan Samuelsen et al.
Antimicrobial agents and chemotherapy, 54(1), 346-352 (2009-11-04)
Scandinavia is considered a region with a low prevalence of antimicrobial resistance. However, the number of multidrug-resistant (MDR) Gram-negative bacteria is increasing, including metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa. In this study MBL-producing P. aeruginosa isolates identified in Norway (n = 4)
Li-Yang Hsu et al.
Antimicrobial agents and chemotherapy, 54(3), 1173-1178 (2010-01-13)
A surveillance study was performed in four Singapore public hospitals from 2006 to 2008 to determine the correlation between antibiotic prescription and Gram-negative bacterial antimicrobial resistance. Targeted organisms included ceftriaxone- and ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae, as well as
Dongeun Yong et al.
Antimicrobial agents and chemotherapy, 53(12), 5046-5054 (2009-09-23)
A Swedish patient of Indian origin traveled to New Delhi, India, and acquired a urinary tract infection caused by a carbapenem-resistant Klebsiella pneumoniae strain that typed to the sequence type 14 complex. The isolate, Klebsiella pneumoniae 05-506, was shown to
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.